DAPA has been proved that it could suppress cardiac fibroblast activation and endothelial-to-mesenchymal transition (EndMT) to protect against myocardial fibrosis via AMP-activated protein kinaseα (AMPKα)-modulated inhibition of TGF-β/Smad signaling (79). The gene discussed is TGFB1; the disease is Myocardial fibrosis.